Agenus Inc. (AGEN): Price and Financial Metrics

Agenus Inc. (AGEN)

Today's Latest Price: $4.08 USD

0.04 (0.99%)

Updated Oct 22 4:00pm

Add AGEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

AGEN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AGEN is -0.44 -- better than merely 6.46% of US stocks.
  • Of note is the ratio of Agenus Inc's sales and general administrative expense to its total operating expenses; merely 11.84% of US stocks have a lower such ratio.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.83 for Agenus Inc; that's greater than it is for merely 6.24% of US stocks.
  • Stocks that are quantitatively similar to AGEN, based on their financial statements, market capitalization, and price volatility, are PLX, ACIU, DNN, LOGC, and IPHA.
  • Visit AGEN's SEC page to see the company's official filings. To visit the company's web site, go to

AGEN Stock Price Chart Interactive Chart >

Price chart for AGEN

AGEN Price/Volume Stats

Current price $4.08 52-week high $5.63
Prev. close $4.04 52-week low $1.82
Day low $4.03 Volume 1,811,500
Day high $4.15 Avg. volume 2,630,426
50-day MA $4.30 Dividend yield N/A
200-day MA $3.46 Market Cap 748.45M

Agenus Inc. (AGEN) Company Bio

Agenus Inc. engages in discovering and developing innovative treatments for patients with cancer and other diseases. The company was founded in 1994 and is based in Lexington, Massachusetts.

AGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

AGEN Latest Social Stream

Loading social stream, please wait...

View Full AGEN Social Stream

Latest AGEN News From Around the Web

Below are the latest news stories about Agenus Inc that investors may wish to consider to help them evaluate AGEN as an investment opportunity.

Agenus First Data From MK-4830: Another Reason To Buy

Although Agenus (AGEN) is a small pharmaceutical company, in terms of its under $1 billion stock market capitalization, it has a remarkably broad pipeline of potential cancer drugs. It has long been a commercial-stage company since it licenses a key ingredient of Shingrix to GlaxoSmithKline (GSK). It hopes to complete...

William Meyers on Seeking Alpha | September 23, 2020

The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reac...

Benzinga | September 11, 2020

Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers

Gainers:  Agenus (AGEN) +13%, Achieve Life Sciences (ACHV) +7%, Agile Therapeutics (AGRX) +7%, Akouos (AKUS) +7%, Adial Pharmaceuticals (ADIL) +6%.Losers: Satsuma Pharmaceuticals STSA -75%, Precipio (PRPO) -22%, Sutro Biopharma (STRO) -18%, Athenex ATNX -16%, Spero Therapeutics (SPRO) -15%....

Seeking Alpha | September 10, 2020

Paul Clark Joins Agenus Board of Directors

LEXINGTON, Mass., Aug. 31, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of…

PR Newswire | August 31, 2020

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit – Therapeutics Day on a Panel entitled Pursuing Curative Cell Therapy Approaches.

Yahoo | July 21, 2020

Read More 'AGEN' Stories Here

AGEN Price Returns

1-mo -4.90%
3-mo 25.93%
6-mo 46.24%
1-year 67.90%
3-year 9.38%
5-year -18.89%
YTD 0.25%
2019 71.01%
2018 -26.99%
2017 -20.87%
2016 -9.25%
2015 14.36%

Continue Researching AGEN

Here are a few links from around the web to help you further your research on Agenus Inc's stock as an investment opportunity:

Agenus Inc (AGEN) Stock Price | Nasdaq
Agenus Inc (AGEN) Stock Quote, History and News - Yahoo Finance
Agenus Inc (AGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6904 seconds.